| Literature DB >> 35627323 |
Piotr Skomro1, Danuta Lietz-Kijak1, Olga Bogdziewicz-Wałęsa1, Joanna Janiszewska-Olszowska2.
Abstract
Extremely Low-Frequency Electromagnetic Field (ELF MF) therapy is effective in the treatment of injury, inflammation and postoperative complications. Its clinical applications relate to bone unification, pain reduction, soft tissue oedema and the decrease of electric potentials in the oral cavity. It enhances regeneration of periapical bone lesions. It is obvious that cells (leukocytes, platelets, keratinocytes, osteoblasts) and proteins (fibrin, collagen, elastin and growth factors) exhibit alterations when exposed to an Extremely Low-Frequency Electromagnetic Field. The aim of the study was to evaluate the effect of an Extremely Low-Frequency Electromagnetic Field (ELF MF) on the parotid gland on the concentration of salivary immunoglobulin A. The study group consisted of 24 patients, aged 14-16, who underwent ELF MF on the parotid gland region. The control group comprised 25 matching persons. The IgA concentration in saliva samples was established using radial immunodiffusion. Following ELF MF, a statistically significant increase in the concentration of secretory immunoglobulin A was found in the study group, whereas in the control group, no statistically significant differences were noted. It can be concluded that an Extremely Low-Frequency Electromagnetic Field increases the activity of the immune system of the parotid gland.Entities:
Keywords: Extremely Low-Frequency Electromagnetic Field; IgA; Viofor JPS device; immunity; paraprobiotics; parotid gland; postbiotics; probiotics; saliva
Mesh:
Substances:
Year: 2022 PMID: 35627323 PMCID: PMC9141657 DOI: 10.3390/ijerph19105786
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1ELF EMF treatment with the use of an elliptical R applicator.
Figure 2Scheme of the application of the ELF EMF of the M1 method and P3 program.
Characteristics of the concentration of immunoglobulin A [mg/mL] in saliva before and after Extremely Low-Frequency Electromagnetic Field therapy in the study group.
| Distribution | Before the | After 5 | After 10 | After 15 |
|---|---|---|---|---|
| n | 24 | 24 | 24 | 24 |
| min–max | 62.5–159.0 | 85.0–159.8 | 99.0–170.2 | 122.7–190.0 |
| Q1–Q3 | 85.6–142.1 | 108.3–150.6 | 121.9–156.2 | 135.5–160.6 |
| me | 100.2 | 127.2 | 137.4 | 156.1 |
| M ± SD | 111.2 ± 31.6 | 127.9 ± 23.8 | 137.6 ± 19.5 | 151.3 ± 17.4 |
| W | 0.911 | 0.921 | 0.951 | 0.939 |
|
| <0.04 | >0.06 | >0.28 | >0.16 |
| Wilcoxon Test |
| |||
n—group size, min—minimum value, max—maximum value, Q1—first quartile, Q3—third quartile, me—median, M—arithmetic average, SD—standard deviation, W—Shapiro–Wilk Test, p–significance level.
Characteristics of the concentration of immunoglobulin A [mg/mL] in saliva in the subsequent examinations of the control group.
| Distribution | 1st Examination | 2nd Examination | 3rd Examination |
|---|---|---|---|
| n | 25 | 25 | 25 |
| min–max | 72.5–170.2 | 67.8–165.3 | 70.3–160.8 |
| Q1–Q3 | 97.7–129.3 | 97.8–130.8 | 97.4–130.5 |
| me | 120.3 | 115.3 | 120.3 |
| M ± SD | 116.2 ± 27.2 | 116.5 ± 29.0 | 117.3 ± 27.0 |
| W | 0.959 | 0.954 | 0.955 |
|
| >0.41 | >0.31 | >0.33 |
| Student’s |
| ||
n—minimum value, max—maximum value, Q1—first quartile, Q3—third quartile, me—median, M—arithmetic average, SD—standard deviation, W—Shapiro–Wilk Test, p—significance level.
Figure 3The mean values of the concentration of immunoglobulin A (mg/mL) in the saliva of patients from the study group (Table 1) and the control group (Table 2).